External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInfanta Leonor University Hospital
About this trial
This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study includes a retrospective cohort of patients with acute symptomatic VTE diagnosed between 2000 and 2022, and a prospective cohort of consecutively recruited patients from December 2025 to December 2027. The CLOVER model will be applied to all participants, and its ability to discriminate between patients with and without occult cancer will be evaluated. The study also assesses clinicians' satisfaction with the web-based tool (CLOVER-Web) developed to facilitate the use of the score in clinical practice.
Eligibility criteria
Qualifiers
Age ≥18 years.
Objectively confirmed acute symptomatic venous thromboembolism (deep vein thrombosis and/or pulmonary embolism).
Ability to provide written or electronic informed consent.
Disqualifiers
Suspicion of cancer during the initial diagnostic evaluation for VTE.
Participation in another interventional study that may interfere with outcomes.
Inability or refusal to provide informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 1 trial groupSponsors and collaborators
Infanta Leonor University Hospital
Lead sponsor
Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor
Collaborator
Source ClinicalTrials.gov